News Wire

Positive results have been reported from a phase 3 trial of cytarabine/daunorubicin liposome for injection (Vyxeos, Celator Pharmaceuticals) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared with the standard-of-care regimen of cytarabine and daunorubicin known as 7+3. The…
Researchers in Germany have developed a blood test that may allow the detection of Alzheimer’s disease (AD) at an early stage. The test consists of an immunochemical analysis using an infrared sensor. The sensor’s surface is coated with antibodies that extract biomarkers for AD from blood or cerebrospinal…
Peter Holden, president and CEO of Beth Israel Deaconess Hospital in Plymouth, Massachusetts, and his peers recently formed a statewide task force under the auspices of the Massachusetts Hospital Association (MHA) and compiled a list of nine best practices to improve the management of opioid use in…
The Centers for Medicare and Medicaid Services (CMS) mandatory program of bundled payments for hip and knee joint replacements is set to take effect on April 1––whether hospitals are ready for it or not. And according to a new survey, most are not. With its first mandatory initiative, the CMS has…
In Europe, pharma regulators have started a review into the safety of the leukemia drug idelalisib (Zydelig, Gilead Sciences) because of concerns over serious adverse events, including deaths, according to a Reuters report. The review was prompted by an increased rate of adverse events, mostly involving…
The FDA has approved a supplemental new drug application for crizotinib (Xalkori, Pfizer) to treat patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors are ROS1-positive. In 2015, the FDA granted breakthrough therapy and priority review designations for this indication. Crizotinib…
Positive results have been reported from a phase 3 study of the investigational medication cannabidiol (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, a rare and debilitating type of infantile-onset epilepsy for which no treatments are currently available in the U.S. Cannabidiol achieved…
A phase 3 monotherapy study has met its primary endpoint, demonstrating that sarilumab (Regeneron Pharmaceuticals/Sanofi) was superior to adalimumab (Humira, AbbVie) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at week 24. The study, SARIL-RA-MONARCH, also met important…
The FDA has accepted for review a supplemental biologics license application (sBLA) for the expanded use of etanercept (Enbrel, Amgen) to treat pediatric patients with chronic severe plaque psoriasis. If approved, etanercept would be the first systemic drug with this indication in the U.S. The sBLA,…
Across the country, more than 50 rural hospitals have closed during the last six years, and another 283 are in fragile financial condition, according to Kaiser Health News. With rural populations long in decline in the U.S., small-town hospitals have lost customers and struggled to keep pace with advancements…
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has announced that it will discuss the new drug application for eteplirsen (Sarepta Therapeutics) on April 25––nearly three months after the original action date. Sarepta is seeking approval for the treatment of Duchenne…
A genetically engineered mosquito being used in the fight against the Zika virus will not have a significant impact on the environment, according to preliminary findings from the FDA. Males of the self-limiting strain of the Aedes aegypti mosquito are modified so that their offspring die before being…
An investigation into a clinical test in France that left one person dead and put five others in a hospital has found evidence of brain damage in people who took high doses of the experimental pain medicine, according to a report from NPR News. The early-stage clinical study was shut down in January…
Two widely used targeted-therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib (Nexavar, Bayer/Onyx Pharmaceuticals) and sunitinib (Sutent, Pfizer)—are no more effective than a placebo in preventing return of the disease, according to a new study from the Abramson…
Positive results have been announced from a phase 2b trial of ixmyelocel-T (Vericel Corporation) in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM). The study met its primary endpoint of demonstrating a reduction in the total number of deaths, cardiovascular hospitalizations,…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA